Latest Articles

Publication Date
All News Scientific
“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer - Oncology News Central

“Unprecedented OS Benefit” Seen in Advanced, Recurrent Endometrial Cancer Oncology News Central

Published: March 17, 2024, 7 a.m.
Read Full Article
KEYNOTE-A18 Eligibility: Pembro/Chemoradiotherapy in Cervical Cancer - Targeted Oncology

KEYNOTE-A18 Eligibility: Pembro/Chemoradiotherapy in Cervical Cancer Targeted Oncology

Published: Jan. 5, 2024, 8 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!